India

BMI Core View: Drugmakers based in emerging markets will increasingly produce hard-to-manufacture pharmaceuticals. Firms in developing countries enjoy low operating costs, but have... 2010-08-19

BMI Core View: The biosimilar sector will become increasingly competitive. Pharmaceutical companies are entering the sector to offset declining revenues from small molecule drugs. A... 2010-08-17

BMI Core View: Offshoring manufacturing to low cost bases will accelerate. Multinational drugmakers are looking to cut costs ahead of the patent cliff and production is being shifted... 2010-07-26

BMI Core View: Sales forces will contract in developed states and expand in emerging markets. The primary cause of this trend is the declining influence of US and Western European doctors... 2010-07-15

BMI's newest core view is that private healthcare spending as a percentage of total healthcare expenditure in emerging markets will decrease over the medium term. Governments in these... 2010-07-05

Like other Japanese pharmaceutical companies, Eisai is conservative in nature and outlook. The Tokyo-based firm generates the majority of revenue in its domestic market and the US.... 2010-06-29

It is BMI's view that Pfizer India needs to enhance its strategy to further improve its financial results. Although the company outpaced some of its multinational rivals in terms of... 2010-06-28